Clover Health Investments Touts AI Medicare Advantage Model, Targets GAAP Profitability in 2026 at Leerink Conference

Clover Health Investments (NASDAQ:CLOV) executives outlined what they described as a repeatable, technology-driven Medicare Advantage model at the Leerink Global Healthcare Conference, emphasizing high member retention, cohort profitability dynamics, and expanding use cases for its software beyond the company’s own health plan.

AI-enabled Medicare Advantage model

Management framed Clover as an “AI-powered Medicare Advantage plan,” saying technology has been central to its business model design for roughly a decade. The company’s approach centers on supporting primary care physicians (PCPs) “at the point of care” with its Clover Assistant platform, which it said is intended to improve clinical outcomes through earlier diagnosis and better treatment while lowering total cost of care over time.

The company contrasted its model with more traditional Medicare Advantage approaches, highlighting a wide network that it said is differentiated versus the HMO-heavy structure common in the market. Clover also said it does not delegate risk, meaning it bears the cost burden of new members who are unprofitable in their first year, but retains the full upside as cohorts mature.

Retention, quality claims, and profitability targets

Clover executives cited member retention of more than 95%, which they characterized as market-leading, and said the company has been the “number one PPO plan in the nation” on HEDIS quality scores for a second year in a row.

On financial performance, the company said it has been EBITDA profitable for the last couple of years and reiterated its expectation for significant growth while improving profitability. Executives also said they have “conviction” in achieving GAAP net income profitability for 2026 while growing “over 50%,” and stated that this year is expected to be its “first full year of GAAP net income profitability” based on its guidance.

Clover Assistant and cohort economics

Management described Clover Assistant as connecting more than 100 medical data sources, including major electronic health records, claims, labs, and pharmacy-related data. Beyond data aggregation, executives said the company’s machine learning models synthesize information into real-time prompts and care management suggestions for physicians, while the PCP retains responsibility for clinical decisions.

Clover also referenced published white papers across chronic conditions including diabetes, congestive heart failure (CHF), chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD). Executives said A/B testing in those studies showed diagnoses generally occurring 18 to 36 months earlier for groups supported by Clover Assistant versus those that were not, and cited reductions in hospitalizations and readmissions as an example of outcomes used to measure impact.

In discussing profitability by member tenure, management said the loss per member per month for new members has been decreasing year-over-year, attributing the trend to improved acquisition economics and earlier care management engagement—particularly for high-acuity members. For returning members, Clover said the model’s economics are “very powerful,” with margin expansion as cohorts mature and total cost of care declines over time. When asked about predictability, executives said cohort performance is “directionally very predictable” and “runs like clockwork.”

Clover added that about 70% of its total membership is covered by physicians using Clover Assistant, with roughly 30% not currently covered by PCPs using the software. The company said it expects to maintain that coverage percentage even as it scales membership.

AEP observations, pricing posture, and home care strategy

Discussing the most recent annual enrollment period (AEP), management said 85% of new members were “switchers” with medical histories that could be obtained from prior plans, which it said was roughly 500 basis points higher than the previous AEP. Executives said early membership indicators, including January and February payment and risk adjustment-related files, were in line with expectations.

On pricing for the 2026 bid, Clover said it applied underwriting discipline and did not assume an improvement in trend. Executives noted that the company’s medical cost trend (Part C excluding pharmacy) was slightly below 5% last year and said it bid for a medical cost trend assumption higher than that level, without disclosing the specific percentage. On pharmacy, Clover referenced initiatives around PBM transparency, pricing or rebates, and formulary management, saying it is seeing improvements, while noting the industry is still adapting to Inflation Reduction Act-related changes.

The company also described its MD-led home care division for the highest acuity members, in which physicians (MDs and DOs) take over primary care and conduct in-home visits while using the same Clover Assistant platform. Management positioned this as a differentiator that supports better health outcomes.

Stars, rate outlook, and Counterpart expansion

For 2026, Clover said it expects a four-star payment year, calling it a tailwind but emphasizing it has designed its model to be “efficient and profitable” even at 3.5 stars and is not dependent on four-star status. Executives said the incremental benefit of quality bonus payments is embedded in guidance and is “significant” year-over-year, though they did not quantify the flow-through given benefit trade-offs.

On the Medicare Advantage rate environment, management said it has not provided a specific expectation for the final rate notice, but believes it will likely be “slightly higher.” Executives added they are not reliant on annual rate increases and suggested that a flatter rate environment could highlight the strength of Clover’s model. Clover also said it believes it is less impacted by proposed CMS changes related to unlinked chart reviews because its model is encounter-based and supported by its platform and medical data.

Separately, Clover discussed its external software offering, Counterpart, aimed at other health plans and risk-bearing providers. Management described progress through a sequence of adoption metrics—landing customer “logos,” onboarding PCP practices, then expanding the number of patients covered by the software and scaling geographically. While noting it is not yet material from a revenue perspective, the company reiterated its near-term target for patients or members covered by Counterpart to equal the number of members in Clover’s own Medicare Advantage plan, describing that timeframe as “somewhere in between” the end of the year and three years out. Executives also said the company wants to retain SG&A flexibility to invest more in Counterpart if momentum accelerates, noting that product development and R&D are included within SG&A classification.

When asked about a Stars-related lawsuit, Clover provided no update on the case’s progression.

About Clover Health Investments (NASDAQ:CLOV)

Clover Health Investments is a technology-driven healthcare company specializing in Medicare Advantage plans for senior populations. The company combines insurance coverage with a proprietary software platform to improve care coordination, outcomes tracking and cost management. By leveraging data analytics, Clover Health aims to deliver personalized care pathways and preventive interventions for its members.

At the core of Clover’s offering is its Clover Assistant platform, which aggregates clinical and claims data from multiple sources to create real-time insights for physicians and care teams.